Adjuvant hormone treatment with radiotherapy has been demonstrated in two studies (Bolla and RTOG 8531) to be beneficial in patients with locally advanced prostate cancer. However, the vast majority of patients with early prostate cancer can be cured with radiotherapy alone. Subset analysis combining RTOG 8610 and RTOG 8531 has demonstrated a survival benefit only for patients with a biopsy Gleason score ≤6 after short-term neoadjuvant hormonal therapy. The results of ongoing research will further clarify the use of hormone treatment with radiotherapy in patients with low and intermediate risk.

Keywords:
Radiotherapy, Prostate cancer, Hormones
1.
Anderson PR, Hanlon AL, Movsas B, Hanks GE: Prostate cancer patients subsets showing improved bNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys 1997;39:1025–1030
2.
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
3.
Bostwick DG, Qian J: Current and proposed biologic markers in prostate cancer. J Cell Biochem 1994;19:197–210.
4.
Crook JM, Perry GA, Robertson S, Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology 1995;45:624–632.
5.
D’Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, Coleman CN: Equivalent biochemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4–20 ng/ml. Int J Radiat Oncol Biol Phys 1997;37:1053–1058.
6.
D’Amico AV: Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology 2001;58:78–82.
7.
D’Amico AV, Schultz D, Loffredo M, et al: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for men with clinically localized prostate cancer. JAMA 2000;284:1280–1283.
8.
Fieldname HJ: Vergleich der Spätnebenwirkungen bei konformaler gegenüber konventioneller Strahlentherapie des lokal begrenzten Prostatakarzinoms. Eine prospektiv randomisierte Studie. Strahlenther Onkol 1999;175:350–351.
9.
Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF: Neo-adjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. CA Invest 1995;13:132–133.
10.
Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753–3761.
11.
Hanks GE, Schultheiss TE, Hunt M, Epstein BE: Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995;31:25–29.
12.
Hanks GE, Lee WR, Hanlon AL, Hunt M, Kaplan E, Epstein BE, Movsas B, Schultheiss TE: Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml. Int J Radiat Oncol Biol Phys 1996;35:861–868.
13.
Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T: Dose selection for prostate cancer patients based on dose comparison and dose-response studies. Int J Radiat Oncol Biol Phys 2000;46:823–832.
14.
Hanks GE, Lu J, Machtay M, et al: RTOG Protocol 92–02: A phase III trial of the use of long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy for locally advanced carcinoma of the prostate (abstract 1284). Proc Am Soc Clin Oncol 2000. J Clin Oncol 2000;19:327a.
15.
Hellstrom M, Haggman M, Brandstedt S: Histopathological changes in androgen-deprived localized prostatic cancer. Eur Urol 1993;24:461–465.
16.
Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, Brabbins DS, Hallander J, Chen PY, Martinez AA: Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996;36:565–571.
17.
Horwitz EM, Winter K, Hanks GE, Lawton CA, Russel AH, Machtay M: Subset analysis of RTOG 85–31 and 86–10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys Oncol 2001;49:947–956.
18.
Huggins C, Hodges CV: Studies on prostate cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–297.
19.
Kupelian PA, Buchsbaum JC, Reddy AC, Klein EA: Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason ≤6, and pretreatment prostate-specific antigen ≤10). Int J Radiat Oncol Biol Phys 2001;50:621–625.
20.
Lavardière J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F: Beneficial effect of combination hormonal therapy administered prior and following external beam irradiation in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247–252.
21.
Lim Joon D, Hasegawa M, Wu CS, et al: Supra-additive apoptotic response in predominantly quiescent prostate tumors, when treated with androgen-ablation and radiotherapy. Int J Radiat Oncol Biol Phys 1996;36:191.
22.
Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA: Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996;35:251–257.
23.
Lubeck DP, Grossfeld GD, Carroll PR: The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001;58:94–99.
24.
Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostetic carcinoma: A randomized comparative trial of the Radiation Therapy Oncoloy Group. Urology 1995;45:616–623.
25.
Pinover WH, Hanlon AL, Horwitz EM, Hanks GE: Defining the appropriate dose for prostate cancer patients with PSA <10 ng/ml. Int J Radiat Oncol Biol Phys 1998;42:142.
26.
Pollack A, Smith LG, von Eschenbach AC: External beam radiotherapy dose response characteristics of 1,127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48:507–512.
27.
Shipely WU: A phase III trial (RTOG 8610) comparing external beam irradiation plus short-term maximal androgen blockade with radiation therapy for locally advanced prostate cancer. Eur Urol 1994;26:3.
28.
Soffen EM, Hanks GE, Hunt MA, Epstein BE: Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992;24:485–488.
29.
Soloway MS, Sharifi R, Wajsman Z, Mc Leod D, Wood DP, Puras-Baez A, for the Lupron depot neoadjuvant prostate study group: Randomized prospective study comparing radical prostatectomy alone vs. radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2b Nx M0) prostate cancer. J Urol 1995;154:424–428.
30.
Yang FE, Chen GT, Ray P, et al: The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:1009–1017.
31.
Zagars GK, Pollack A, von Eschenbach AC: Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 1997;80:764–765.
32.
Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491–500.
33.
Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, Fuks C: Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994;29:755–761.
34.
Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, Liebel SA: Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998;16:3380–3385.
35.
Zierhut D, Flentje M, Sroka-Perez G, Rudat V, Engenhart-Cabillic R, Wannenmacher M: The conformal radiotherapy of localized prostatic carcinoma: Acute tolerance and early efficacy. Strahlenther Onkol 1997;173:98–105.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.